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The biology and clinical practice of stem cell transplantation is advancing at a rapid pace. Progress in preclinical
models is rooted in 50 years’ history of elegant experimentation in stem cell biology, transplantation immu-
nology and immunogenetics. Current clinical trials are based on these studies, as well as a series of careful
clinical studies that have built progressively over the past decades as well. The Plenary Sessions of this year’s
combined annual meetings of ASBMT and CIBMTR, and this inaugural Education Book, include both
historical overviews and snapshots of the most recent advances in critical facets of experimental and clinical
transplantation.
In the ﬁrst Plenary Session, Dr. Armand Keating, President of the ASBMT, leads an analysis of the most
provocative recent data relevant to the ability of hematopoietic stem cells to regenerate myocardium in vivo
after infarction. Drs. Keating and Helmut Drexler discuss speciﬁc animal models and their relevance to the
clinical scenario, as well as critically review the studies presented and published to date. In addition to the work
summarized in these chapters, the most recent, breaking news in this ﬁeld is covered during the session as well.
Dr. John Dick leads the second Plenary Session in presenting the case for applying the stem cell model to
cancer. Dr. Dick discusses the incredible parallels between normal and leukemic hematopoietic compartments
in terms of their hierarchies of differentiated cells, and Dr. Michael Clarke identiﬁes analogous issues in solid
tumors. In both cases these studies have profound implications for therapy, simultaneously identifying poten-
tially the only important cells to eradicate in cancer therapy while suggesting why it is that complete clinical
remissions so often do not equate with cures. Dr. Peter Dirks applies these notions to the central nervous
system, where the identiﬁcation and localization of brain tumor stem cells also may illuminate the normal
developmental geometry of neural pathways.
Graft-versus-host disease (GVHD) is the subject of the third Plenary Session, led by Dr. Olle Ringde´n of
the Karolinska University Hospital. Dr. Ringde´n reviews the clinical complexity of acute and chronic GVHD,
and what we have learned from now-classic trials of immunosuppression for prophylaxis and therapy. Dr.
George Sale discusses the pathology and pathophysiology of GVHD, which points to new potential avenues for
GVHD control. John Hansen then reviews very exciting recent advances in immunogenetics, which hold the
promise to allow for very precise risk predictions of GVHD, and therefore for donor selection and stratiﬁcation
of prophylaxis.
Dr. Stephen Forman summarizes the current status of high-dose hematopoietic stem cell rescue for cancer
in the fourth Plenary Session. Dr. Michael Jensen details the exciting therapeutic application of naive and
genetically engineered T cells. These are particularly exciting, holding the promise as therapy that is not tumor
cell–cycle dependent, and which thereby might target tumor stem cells. Dr. Fred Applebaum concludes the
session by updating the latest advances in targeted radioimmunotherapy in autologous bone marrow trans-
plantation.
Allogenic transplantation provides the potential for T-cell therapy not available in unmodiﬁed autologous
transplants, but GVHD and poor immunoreconstitution severely hinder its safe application. Dr. Joseph Antin
provides an analytic overview of immunologic failure after allogeneic stem cell transplantation, reviewing both
the immunologic principles and the real-world complications seen in the clinic. Dr. Bruce Blazar then describes
the discovery, characterization, and application of regulatory T cells to allotransplantation. As he details, this
relatively rare T cell population, if expanded and included along with standard allotransplants, holds the
potential to aid immune reconstitution while not worsening GVHD.
Together, these presentations provide a current view of some of the most recent advances in stem cell
transplantation science and practice, taken in the context of the problems and opportunities of the clinic. We
hope that these presentations, and those that follow in the years to come, pave the way for continued progress
and application in stem cell transplantation in hematology, oncology, and medicine most broadly.
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